Dorzolamide

doi:10.2165/00002512-199710050-00006

Paper

Dorzolamide

Published 1997 · J. A. Balfour, M. I. Wilde

Drugs & Aging

Q1 SJR score

74

Citations

2

Influential Citations

Full textSemantic Scholar

Abstract

Dorzolamide (dorzolamide hydrochloride), the first topical carbonic anhydrase (CA) inhibitor to become available for clinical use, lowers intraocular pressure (IOP) by reducing aqueous humour formation. It is formulated as a 2% eyedrop for use in the management of glaucoma and ocular hypertension. When administered 3 times daily, dorzolamide is effective in lowering IOP in patients with open-angle glaucoma or ocular hypertension. Mean IOP was reduced by approximately 4 to 6 mm Hg at peak (2 hours postdose) and 3 to 4.5 mm Hg at trough (8 hours postdose) in clinical trails. A 1-year comparative study showed that the ocular hypotensive efficacy of dorzolamine 2% 3 times daily was similar to that of betaxolol 0.5% twice daily, but slightly inferior to that of timolol 0.5% twice daily. Dorzolamide has additive ocular hypotensive effects when used in conjunction with topical beta-adrenergic antagonists and was as effective as pilocarpine 2% 4 times daily as adjunctive therapy in patients receiving timolol. Dorzolamide does not appear to produce the acid-base or electrolyte disturbances and severe systemic adverse events associated with oral CA inhibitors, and unlike beta-adrenergic antagonists, it is not contraindicated in patients with asthma, reactive airways disease or heart disease. Furthermore, as CA inhibitors do not cause miosis, they may cause less interference with vision than pilocarpine or epinephrine (adrenaline). The most common adverse effects associated with dorzolamide are bitter taste and transient local burning or stinging. Conjunctivitis was the most common reason for discontinuation of dorzolamide in one large study. Thus, available data suggest that dorzolamide has potential as an alternative therapy option in patients with glaucoma or ocular hypertension who are intolerant of, or unable to receive, ophthalmic beta-adrenergic antagonists and as adjunctive therapy in patients already receiving these agents. Further efficacy and tolerability data are needed to determine the place of dorzolamide in therapy.

Literature Review

Highly Cited

Study Snapshot

Dorzolamide is an effective and safe alternative for lowering intraocular pressure in glaucoma and ocular hypertension patients intolerant of or unable to receive ophthalmic beta-adrenergic antagonists.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Dorzolamide

Sign up to use Study Snapshot

References

Citations

pH in the vertebrate retina and its naturally occurring and pathological changes

Vertebrate retinae maintain pH homeostasis through metabolic production and buffering, with light-induced alkalinization and circadian rhythms.

Drugs and Their Mode of Action: A Review on Sulfur-Containing Heterocyclic Compounds

Sulfur-containing heterocyclic compounds show diverse pharmacological activities and unique modes of action, with ring size influencing medicinal potency and their potential as drug candidates for treating various diseases.

Quality by design steered approach for co-encapsulation of timolol maleate and dorzolamide hydrochloride in injectable liposomes.

Quality by Design principles successfully developed injectable liposomes coloaded with timolol maleate and dorzolamide HCl, improving intraocular pressure reduction and overcoming limitations of conventional eye drops.

CRISPR-Cas9-mediated deletion of carbonic anhydrase 2 in the ciliary body to treat glaucoma

CRISPR-Cas9-mediated disruption of Car2 in the ciliary body effectively reduces intraocular pressure and delays glaucomatous damage, offering potential benefits for glaucoma patients.

Whiter and Greener RP-HPLC Method for Simultaneous Determination of Dorzolamide, Brinzolamide, and Timolol Using Isopropanol as a Sustainable Organic Solvent in the Mobile Phase

The developed method for simultaneous determination of dorzolamide, brinzolamide, and timolol using isopropanol as a sustainable organic solvent shows good accuracy and precision.

Chemical Insights into Topical Agents in Intraocular Pressure Management: From Glaucoma Etiopathology to Therapeutic Approaches

Topical agents play a crucial role in glaucoma treatment, enhancing patient compliance and drug delivery efficiency.

Three Major Causes of Metabolic Retinal Degenerations and Three Ways to Avoid Them

Herbal medicines, internal neuroprotective substances, and synthetic drugs targeting four processes can potentially prevent or treat metabolic retinal degenerations like age-related alterations, diabetic retinopathy, and glaucoma.